Posted On: 06/09/2016 12:18:11 AM
Post# of 273315
Trxade Group Inc (TRXD) 0.9000 $TRXD
Trxade Group Achieves Record First Quarter 2016 Financial Results Driven by a 165% Increase in Revenues Over First Quarter 2015
GlobeNewswire - Thu Apr 21, 8:15AM CDT
First Quarter Highlights:
Trxade Group Achieves Record Fourth Quarter and Fiscal 2015 Financial Results
GlobeNewswire - Tue Mar 29, 8:12AM CDT
Highlights:
UPDATE -- Trxade Group, Inc. Launches HCTZ (Hydrochlorothiazide) to Treat Fluid Edema
GlobeNewswire - Tue Feb 09, 1:05PM CST
Trxade Group, Inc. (OTCQB:TRXD), a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, today announced that its wholly-owned subsidiary, Westminster Pharmaceuticals LLC ("Westminster"
, has launched the generic drug HCTZ (Hydrochlorothiazide) as part of an agreement with ScieGen Pharmaceuticals, Inc. ScieGen's ANDA Number 203018 for Hydrochlorothiazide treats fluid retention (edema) in people with congestive heart failure, cirrhosis of the liver, kidney disorders, or edema caused by taking steroids or estrogen. This medication, which is also used to treat high blood pressure (hypertension), will be marketed under the Westminster Pharmaceuticals, LLC private label. Under the terms of the supply and distribution agreement with ScieGen, Westminster will semi-exclusively market and distribute ScieGen's product in the United States.
Trxade Group, Inc. Launches HCTZ (Hydrochlorothiazide) to Treat Fluid Edema
GlobeNewswire - Tue Feb 09, 10:07AM CST
Trxade Group, Inc. (OTCQB:TRXD), a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, today announced that its wholly-owned subsidiary, Westminster Pharmaceuticals LLC ("Westminster", has launched the generic drug HCTZ (Hydrochlorothiazide) as part of an exclusive agreement with ScieGen Pharmaceuticals, Inc. ScieGen's ANDA Number 203018 for Hydrochlorothiazide treats fluid retention (edema) in people with congestive heart failure, cirrhosis of the liver, kidney disorders, or edema caused by taking steroids or estrogen. This medication, which is also used to treat high blood pressure (hypertension), will be marketed under the Westminster Pharmaceuticals, LLC private label. Under the terms of the supply and distribution agreement with ScieGen, Westminster will semi-exclusively market and distribute ScieGen's product in the United States.
Trxade Group, Inc. Pharmacy Customer Network Grows to 5,000
GlobeNewswire - Wed Dec 02, 8:14AM CST
Trxade Group, Inc., (OTCQB:TRXD) a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, announced today that it added 400 new customers to its network of independent pharmacy users, bringing the total to 5,000 pharmacies.
Trxade Group, Inc. Reports Record Third Quarter Financial Results
GlobeNewswire - Mon Nov 02, 8:13AM CST
Third Quarter Highlights:
Trxade Group Retains Investor Relations Partners as Investor Relations Counsel
GlobeNewswire - Thu Oct 29, 8:13AM CDT
Trxade Group, Inc. (OTCQB:TRXD), a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, today announced that it has retained Investor Relations Partners (IRP) to expand the Company's strategic investor relations program.
Fundamental Research Corp Announces It Initiated Coverage of Trxade Group, Inc.
Marketwired - Thu Oct 01, 8:00AM CDT
Trxade Group, Inc., (OTCQB: TRXD) is a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally (wholesalers). Currently, the company's market platform is used mainly by around 4,300 retail pharmacies to purchase drugs from 24 wholesalers (supplier to pharmacy). Proprietary software enables users of Trxade's network to compare prices of branded and generic drugs, and order products at the most favorable prices prevailing at the time of the search. As wholesale price disparities among vendors are most pronounced in generic drugs, the retail pharmacies' searches tend to focus on this segment of the market.
Another Supplier Partner Joins Trxade Group Rx Trading Platform
Marketwired - Thu Sep 17, 8:01AM CDT
Trxade Group, Inc. (OTCQB: TRXD), a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, is excited to announce that Paragon Meds, a national pharmaceutical wholesale distributor located out of Weston, FL, has just joined our trading marketplace as our newest Trxade Supplier Partner.
Trxade Group CEO to Present at the Global Chinese Financial Forum (GCFF) Toronto Conference 2015
Marketwired - Thu Sep 03, 8:00AM CDT
Trxade Group, Inc. (OTCQB: TRXD), a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, announced today that Suren Ajjarapu, Chairman and CEO, is scheduled to present at the upcoming 16th Annual Global Chinese Financial Forum (GCFF) Conference on Saturday, September 26th, 2015. The 2015 GCFF Conference will be held in Toronto, Courtyard By Marriott, Toronto Northeast/Markham.
Trxade Group, Inc. Appoints Leading Pharmaceutical Industry Expert Mr. Donald Anderson to Its Advisory Board
Marketwired - Tue Jul 21, 9:03AM CDT
Trxade Group, Inc. (OTCQB: TRXD), a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, announced today the appointment of Donald W. Anderson to the Company's advisory board. The newly appointed member would serve as a strategic resource to Trxade Group as it continues to develop its trade relationships in the industry.
Trxade Group CEO to Present at the 2015 LD Micro Invitational Conference in Los Angeles on June 2nd
Marketwired - Thu May 28, 8:00AM CDT
Trxade Group, Inc. (OTCQB: TRXD), a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, announced today that Suren Ajjarapu, Chairman and CEO, is scheduled to present at the upcoming LD Micro Invitational Conference on Tuesday, June 2nd, 2015. The 2015 LD Micro Invitational Conference will be held in Los Angeles at the Luxe Sunset Boulevard Hotel.
Trxade Group, Inc. Reports Increase in 2015 First Quarter Financial and Operational Results
ACCESSWIRE - Wed May 06, 9:26AM CDT
TAMPA, FL / ACCESSWIRE / May 6, 2015 / Trxade Group, Inc., (OTCQB: TRXD) a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, announced today its financial and operational results for first quarter 2015.
Taglich Brothers Issues Updated Research Report
ACCESSWIRE - Thu Apr 02, 6:15PM CDT
TAMPA, FL / ACCESSWIRE / April 2, 2015 / Trxade Group, Inc., (OTCQB: TRXD) a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, On March 26th, 2015 filed their 10K Annual Report that reflects significant increase in revenues from 2013. Also announced today that Taglich Brothers published an updated report on Trxade Group, Inc. on March 31st, 2015.
Trxade Group, Inc. Expands its Board of Directors with Appointment of Independent Director
ACCESSWIRE - Tue Dec 23, 11:43AM CST
TAMPA, FL / ACCESSWIRE / December 23, 2014 / Trxade Group, Inc., (OTCQB: TRXD) a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, announced today the appointment of Donald V Almeida to the Company's Board of Directors. With these additions, the Trxade Group Board now comprises five directors; three of them are independent.
Trxade Group, Inc. Reports Q3 Results With Total Revenues Up 29% and Gross Profit Up 24% From Q2 2014
ACCESSWIRE - Fri Oct 31, 8:00AM CDT
TAMPA, FL / ACCESSWIRE / October 31, 2014 / Trxade Group, Inc., (OTCQB: TRXD) a web-based pharmaceutical marketplace engaged in promoting and enabling purchases between independent pharmacies and large pharmaceutical suppliers nationally, announced today its financial and operational results for third quarter 2014.
Trxade Group, Inc. Advances to Direct Sales Model Utilizing Existing Pharmaceutical Network
Marketwire - Tue Sep 30, 9:32AM CDT
Trxade Group, Inc. (OTCQB: TRXD), a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, announced the launch of our new direct sales model through our wholly owned subsidiary, Westminster Pharmaceuticals, LLC. Westminster Pharmaceuticals will usher in an entirely new profit model for the company, allowing us direct market distribution for Private Label of Pharmaceuticals, pre-formulation, formulation development, scale-up, technical transfer of Tablets, Semi Solids, Oral Liquids, Topical applications and Non-sterile Liquids for Abbreviated New Drug Application/New Drug Application (ANDA/NDA) filing with Quality by Design (QBD) concept. In connection with this exciting new profit center, Dr. Ramesh Kenchappa, M.S.(Pharma), Ph.D., is joining the Company as Chief Scientific Officer. Dr. Ramesh will manage the Research & Development team at Westminster Pharmaceuticals.
Trxade Group Provides Trading Platforms to Pharmacies and Suppliers
Marketwire - Tue Sep 23, 1:00PM CDT
Trxade Group, Inc (OTCQB: TRXD) was recently added to the Bulletin Board and changed their ticker symbol to TRXD. Their CEO, Suren Ajjarapu, spoke with WSA about the company's recent activities and initiatives. He outlined TRXD's unique trading platforms and how they bring pharmaceutical buyers and sellers together by providing distribution solutions to independent pharmacies within a cloud-based environment. He explained that this allows for greater purchasing efficiency, pricing transparency, and means of product sourcing to meet their desired transaction needs. Mr. Ajjarapu outlined these three distinct platforms, S2P (supplier-to-pharmacy), P2P (pharmacy-to-pharmacy), and the most recently added, S2S (supplier-to-supplier). He stated that pharmacies do not have a well-defined means of product sourcing other than buying from their primary vendor and that Trxade offers them value, product availability, and a streamlined, centralized means of purchasing. He also discussed some of the company's recent service offerings, namely the RxGuru app and the Bulk Upload app, which enhance the purchasing efforts for pharma buyers by providing a user-friendly trading platform with proprietary data analytics that can show them the information on pharmaceuticals that are in short supply. He also identified recent market trends, discussed the company's goals for the upcoming year, and provided reasons why investors should consider the stock.
Trxade Group Achieves Record First Quarter 2016 Financial Results Driven by a 165% Increase in Revenues Over First Quarter 2015
GlobeNewswire - Thu Apr 21, 8:15AM CDT
First Quarter Highlights:
Trxade Group Achieves Record Fourth Quarter and Fiscal 2015 Financial Results
GlobeNewswire - Tue Mar 29, 8:12AM CDT
Highlights:
UPDATE -- Trxade Group, Inc. Launches HCTZ (Hydrochlorothiazide) to Treat Fluid Edema
GlobeNewswire - Tue Feb 09, 1:05PM CST
Trxade Group, Inc. (OTCQB:TRXD), a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, today announced that its wholly-owned subsidiary, Westminster Pharmaceuticals LLC ("Westminster"
, has launched the generic drug HCTZ (Hydrochlorothiazide) as part of an agreement with ScieGen Pharmaceuticals, Inc. ScieGen's ANDA Number 203018 for Hydrochlorothiazide treats fluid retention (edema) in people with congestive heart failure, cirrhosis of the liver, kidney disorders, or edema caused by taking steroids or estrogen. This medication, which is also used to treat high blood pressure (hypertension), will be marketed under the Westminster Pharmaceuticals, LLC private label. Under the terms of the supply and distribution agreement with ScieGen, Westminster will semi-exclusively market and distribute ScieGen's product in the United States. Trxade Group, Inc. Launches HCTZ (Hydrochlorothiazide) to Treat Fluid Edema
GlobeNewswire - Tue Feb 09, 10:07AM CST
Trxade Group, Inc. (OTCQB:TRXD), a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, today announced that its wholly-owned subsidiary, Westminster Pharmaceuticals LLC ("Westminster"
, has launched the generic drug HCTZ (Hydrochlorothiazide) as part of an exclusive agreement with ScieGen Pharmaceuticals, Inc. ScieGen's ANDA Number 203018 for Hydrochlorothiazide treats fluid retention (edema) in people with congestive heart failure, cirrhosis of the liver, kidney disorders, or edema caused by taking steroids or estrogen. This medication, which is also used to treat high blood pressure (hypertension), will be marketed under the Westminster Pharmaceuticals, LLC private label. Under the terms of the supply and distribution agreement with ScieGen, Westminster will semi-exclusively market and distribute ScieGen's product in the United States. Trxade Group, Inc. Pharmacy Customer Network Grows to 5,000
GlobeNewswire - Wed Dec 02, 8:14AM CST
Trxade Group, Inc., (OTCQB:TRXD) a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, announced today that it added 400 new customers to its network of independent pharmacy users, bringing the total to 5,000 pharmacies.
Trxade Group, Inc. Reports Record Third Quarter Financial Results
GlobeNewswire - Mon Nov 02, 8:13AM CST
Third Quarter Highlights:
Trxade Group Retains Investor Relations Partners as Investor Relations Counsel
GlobeNewswire - Thu Oct 29, 8:13AM CDT
Trxade Group, Inc. (OTCQB:TRXD), a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, today announced that it has retained Investor Relations Partners (IRP) to expand the Company's strategic investor relations program.
Fundamental Research Corp Announces It Initiated Coverage of Trxade Group, Inc.
Marketwired - Thu Oct 01, 8:00AM CDT
Trxade Group, Inc., (OTCQB: TRXD) is a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally (wholesalers). Currently, the company's market platform is used mainly by around 4,300 retail pharmacies to purchase drugs from 24 wholesalers (supplier to pharmacy). Proprietary software enables users of Trxade's network to compare prices of branded and generic drugs, and order products at the most favorable prices prevailing at the time of the search. As wholesale price disparities among vendors are most pronounced in generic drugs, the retail pharmacies' searches tend to focus on this segment of the market.
Another Supplier Partner Joins Trxade Group Rx Trading Platform
Marketwired - Thu Sep 17, 8:01AM CDT
Trxade Group, Inc. (OTCQB: TRXD), a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, is excited to announce that Paragon Meds, a national pharmaceutical wholesale distributor located out of Weston, FL, has just joined our trading marketplace as our newest Trxade Supplier Partner.
Trxade Group CEO to Present at the Global Chinese Financial Forum (GCFF) Toronto Conference 2015
Marketwired - Thu Sep 03, 8:00AM CDT
Trxade Group, Inc. (OTCQB: TRXD), a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, announced today that Suren Ajjarapu, Chairman and CEO, is scheduled to present at the upcoming 16th Annual Global Chinese Financial Forum (GCFF) Conference on Saturday, September 26th, 2015. The 2015 GCFF Conference will be held in Toronto, Courtyard By Marriott, Toronto Northeast/Markham.
Trxade Group, Inc. Appoints Leading Pharmaceutical Industry Expert Mr. Donald Anderson to Its Advisory Board
Marketwired - Tue Jul 21, 9:03AM CDT
Trxade Group, Inc. (OTCQB: TRXD), a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, announced today the appointment of Donald W. Anderson to the Company's advisory board. The newly appointed member would serve as a strategic resource to Trxade Group as it continues to develop its trade relationships in the industry.
Trxade Group CEO to Present at the 2015 LD Micro Invitational Conference in Los Angeles on June 2nd
Marketwired - Thu May 28, 8:00AM CDT
Trxade Group, Inc. (OTCQB: TRXD), a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, announced today that Suren Ajjarapu, Chairman and CEO, is scheduled to present at the upcoming LD Micro Invitational Conference on Tuesday, June 2nd, 2015. The 2015 LD Micro Invitational Conference will be held in Los Angeles at the Luxe Sunset Boulevard Hotel.
Trxade Group, Inc. Reports Increase in 2015 First Quarter Financial and Operational Results
ACCESSWIRE - Wed May 06, 9:26AM CDT
TAMPA, FL / ACCESSWIRE / May 6, 2015 / Trxade Group, Inc., (OTCQB: TRXD) a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, announced today its financial and operational results for first quarter 2015.
Taglich Brothers Issues Updated Research Report
ACCESSWIRE - Thu Apr 02, 6:15PM CDT
TAMPA, FL / ACCESSWIRE / April 2, 2015 / Trxade Group, Inc., (OTCQB: TRXD) a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, On March 26th, 2015 filed their 10K Annual Report that reflects significant increase in revenues from 2013. Also announced today that Taglich Brothers published an updated report on Trxade Group, Inc. on March 31st, 2015.
Trxade Group, Inc. Expands its Board of Directors with Appointment of Independent Director
ACCESSWIRE - Tue Dec 23, 11:43AM CST
TAMPA, FL / ACCESSWIRE / December 23, 2014 / Trxade Group, Inc., (OTCQB: TRXD) a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, announced today the appointment of Donald V Almeida to the Company's Board of Directors. With these additions, the Trxade Group Board now comprises five directors; three of them are independent.
Trxade Group, Inc. Reports Q3 Results With Total Revenues Up 29% and Gross Profit Up 24% From Q2 2014
ACCESSWIRE - Fri Oct 31, 8:00AM CDT
TAMPA, FL / ACCESSWIRE / October 31, 2014 / Trxade Group, Inc., (OTCQB: TRXD) a web-based pharmaceutical marketplace engaged in promoting and enabling purchases between independent pharmacies and large pharmaceutical suppliers nationally, announced today its financial and operational results for third quarter 2014.
Trxade Group, Inc. Advances to Direct Sales Model Utilizing Existing Pharmaceutical Network
Marketwire - Tue Sep 30, 9:32AM CDT
Trxade Group, Inc. (OTCQB: TRXD), a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, announced the launch of our new direct sales model through our wholly owned subsidiary, Westminster Pharmaceuticals, LLC. Westminster Pharmaceuticals will usher in an entirely new profit model for the company, allowing us direct market distribution for Private Label of Pharmaceuticals, pre-formulation, formulation development, scale-up, technical transfer of Tablets, Semi Solids, Oral Liquids, Topical applications and Non-sterile Liquids for Abbreviated New Drug Application/New Drug Application (ANDA/NDA) filing with Quality by Design (QBD) concept. In connection with this exciting new profit center, Dr. Ramesh Kenchappa, M.S.(Pharma), Ph.D., is joining the Company as Chief Scientific Officer. Dr. Ramesh will manage the Research & Development team at Westminster Pharmaceuticals.
Trxade Group Provides Trading Platforms to Pharmacies and Suppliers
Marketwire - Tue Sep 23, 1:00PM CDT
Trxade Group, Inc (OTCQB: TRXD) was recently added to the Bulletin Board and changed their ticker symbol to TRXD. Their CEO, Suren Ajjarapu, spoke with WSA about the company's recent activities and initiatives. He outlined TRXD's unique trading platforms and how they bring pharmaceutical buyers and sellers together by providing distribution solutions to independent pharmacies within a cloud-based environment. He explained that this allows for greater purchasing efficiency, pricing transparency, and means of product sourcing to meet their desired transaction needs. Mr. Ajjarapu outlined these three distinct platforms, S2P (supplier-to-pharmacy), P2P (pharmacy-to-pharmacy), and the most recently added, S2S (supplier-to-supplier). He stated that pharmacies do not have a well-defined means of product sourcing other than buying from their primary vendor and that Trxade offers them value, product availability, and a streamlined, centralized means of purchasing. He also discussed some of the company's recent service offerings, namely the RxGuru app and the Bulk Upload app, which enhance the purchasing efforts for pharma buyers by providing a user-friendly trading platform with proprietary data analytics that can show them the information on pharmaceuticals that are in short supply. He also identified recent market trends, discussed the company's goals for the upcoming year, and provided reasons why investors should consider the stock.
(0)
(0)
